ClinicalTrials.Veeva

Menu

Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy

A

AMO Pharma

Status

Conditions

Congenital Myotonic Dystrophy

Treatments

Drug: Tideglusib

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT07119775
AMO-02 Expanded Access

Details and patient eligibility

About

This treatment plan is limited to a single patient with Congenital Myotonic Dystrophy, who is ineligible or otherwise unable to participate in ongoing clinical trials.

Sex

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Trial contacts and locations

0

Loading...

Central trial contact

Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems